Search academic texts

Information × Registration Number 0221U000075, 0118U007361 , R & D reports Title To develop technology of antimycobacterial therapy with use of new drugs in patients with resistant lung tuberculosis popup.stage_title Head Lytvynenko Nataliia A, Registration Date 02-01-2021 Organization State organization "National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky National academy of medical sciences of Ukraine" popup.description2  Object - 2049 patients with MDR TB. Aim: to determine optimal algorithms for prescribing reduced and individualized regimens for antimycobacterial therapy for patients with chemoresistant pulmonary tuberculosis, which will improve treatment efficiency and save public money. Methods: clinical, radiological, laboratory, microbiological. The tactics of interpretation of discordant results and the frequency of resistance to fluoroquinolones by gDST – in 23,3–41,3 % were established. The MBT resistance profile was studied, the tendency to increase the primary resistance to fluoroquinolones from 0% to 30,0 % was established. Compared direct and long-term results of 2 modified shortened regimens with the inclusion of new drugs: bedaquiline-based regimens with the inclusion of moxifloxacin or levofloxacin and clofazimine, lead to successful treatment without recurrence for 12 months in all patients, with better tolerability of the moxib regimen. It is established that the use of advanced individualized regimens of 12–13 months lasts successful treatment in 94,2 % of patients - without recurrence within 12–24 months. In patients with resistance to fluoroquinolones, additional administration of delamanide increases the results. The effect of psychological support and video-DOT, which reduced breaks in treatment by 5.3%, was studied. An algorithm for the treatment of a shortened fully oral AMBT regimen has been developed, the use of which allowed all patients to achieve a negative culture of MBT after 2.0 months against the background of the lack of a link between serious PR and new drugs. A method of treating patients with rifampicin-resistant pulmonary TB was developed, which increased the frequency of bacterial cessation and disappearance of clinical manifestations by 44,1 %, reduced by 32,9 % progression and the incidence of PR by 24,2 %. Sphere of application – tuberculosis. Product Description popup.authors Isaakidi Petros Barbova Anna I Blyznyuk Oleksandr P Veselovsʹkyy Leonid V Vorobchenko Tetyana M Heidi Suzanne N Hordiyo Fabiola H Hritsova Nataliya A Hrankina Nataliia V Didyk Vitaliy S Davydenko Valentyna V Dechavez Marve D Donchuk Dmytro Yu Zhurylo Oleksandr A Zaykov Serhiy V Zaytseva Olʹha S Kim Alex Korotchenko Svitlana P Kuzhko Mykhaylo M Lafeta Anastasiya S Lytvynenko Nataliya A Pohrebna Maryna V Protsyk Lyubomyr M Ramzan Nina I Siomak Olʹha V Senʹko Yuliya O Terleyeva Yana S Furin Dzhennifer Khachatur Malakyan Chinmay Shankar L Chobotar Oksana P Shcherbakova Lesya V popup.nrat_date 2021-01-02 Close